clofibric acid has been researched along with Diabetes Mellitus, Type 1 in 5 studies
Clofibric Acid: An antilipemic agent that is the biologically active metabolite of CLOFIBRATE.
clofibric acid : A monocarboxylic acid that is isobutyric acid substituted at position 2 by a p-chlorophenoxy group. It is a metabolite of the drug clofibrate.
Diabetes Mellitus, Type 1: A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study was to study the effect of adding polyunsaturated fatty acid (PUFA) n-3 or placebo (containing oleic acid) to a combined statin-fibrate treatment on plasma lipoproteins, lipoperoxidation, glucose homeostasis, total homocysteine (tHcy) and microalbuminuria (MA) in patients with diabetic dyslipidemia (DDL)." | 5.12 | N-3 fatty acid supplementation decreases plasma homocysteine in diabetic dyslipidemia treated with statin-fibrate combination. ( Písaríková, A; Stanková, B; Tvrzická, E; Vecka, M; Zák, A; Zeman, M, 2006) |
| "Etofibrate is a hypolipemic drug belonging to the fibrate class." | 2.69 | Etofibrate decreases factor VII and fibrinogen levels in patients with polymetabolic syndrome. ( Chelstowski, K; Jastrzebska, M; Kopciewicz, J; Naruszewicz, M; Pieczul-Mróz, J; Torbus-Lisiecka, B, 1999) |
| "Adult patients with type 1 diabetes mellitus (n = 533; 256 men, 277 women; age: 35." | 1.35 | [Effectiveness of cardiometabolic risk reduction in patients with type 1 diabetes mellitus]. ( Fövényi, J; Gaál, Z; Gyimesi, A; Hídvégi, T; Hosszúfalusi, N; Jermendy, G; Nádas, J; Neuwirth, G; Oroszlán, T; Pánczél, P; Putz, Z; Vándorfi, G; Winkler, G; Wittmann, I, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 4 (80.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nádas, J | 1 |
| Putz, Z | 1 |
| Fövényi, J | 1 |
| Gaál, Z | 1 |
| Gyimesi, A | 1 |
| Hídvégi, T | 1 |
| Hosszúfalusi, N | 1 |
| Neuwirth, G | 1 |
| Oroszlán, T | 1 |
| Pánczél, P | 1 |
| Vándorfi, G | 1 |
| Winkler, G | 1 |
| Wittmann, I | 1 |
| Jermendy, G | 1 |
| Candido, R | 1 |
| Zanetti, M | 1 |
| Zeman, M | 1 |
| Zák, A | 1 |
| Vecka, M | 1 |
| Tvrzická, E | 1 |
| Písaríková, A | 1 |
| Stanková, B | 1 |
| Geiss, HC | 1 |
| Parhofer, K | 1 |
| Jastrzebska, M | 1 |
| Torbus-Lisiecka, B | 1 |
| Pieczul-Mróz, J | 1 |
| Chelstowski, K | 1 |
| Kopciewicz, J | 1 |
| Naruszewicz, M | 1 |
1 review available for clofibric acid and Diabetes Mellitus, Type 1
| Article | Year |
|---|---|
Current perspective. Diabetic vascular disease: from endothelial dysfunction to atherosclerosis.
Topics: Angiotensin-Converting Enzyme Inhibitors; Atherosclerosis; Blood Coagulation Factors; Clofibric Acid | 2005 |
2 trials available for clofibric acid and Diabetes Mellitus, Type 1
| Article | Year |
|---|---|
N-3 fatty acid supplementation decreases plasma homocysteine in diabetic dyslipidemia treated with statin-fibrate combination.
Topics: Adult; Albuminuria; Cholesterol Esters; Clofibric Acid; Diabetes Mellitus, Type 1; Dietary Supplemen | 2006 |
Etofibrate decreases factor VII and fibrinogen levels in patients with polymetabolic syndrome.
Topics: Arteriosclerosis; Clofibric Acid; Diabetes Mellitus, Type 1; Factor VII; Fibrinogen; Humans; Hyperli | 1999 |
2 other studies available for clofibric acid and Diabetes Mellitus, Type 1
| Article | Year |
|---|---|
[Effectiveness of cardiometabolic risk reduction in patients with type 1 diabetes mellitus].
Topics: Adult; Anticholesteremic Agents; Antihypertensive Agents; Azetidines; Blood Pressure; Body Mass Inde | 2008 |
[Diabetic dyslipoproteinemia].
Topics: Blood Glucose; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Diabetes Mellitus, Type 1; Diabet | 2006 |